Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient
- PMID: 36862401
- PMCID: PMC10373857
- DOI: 10.1097/ALN.0000000000004520
Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient
Abstract
Inherited and acquired coagulopathy are frequently associated with major bleeding in severe trauma, cardiac surgery with cardiopulmonary bypass, and postpartum hemorrhage. Perioperative management is multifactorial and includes preoperative optimization and discontinuation of anticoagulants and antiplatelet therapy in elective procedures. Prophylactic or therapeutic use of antifibrinolytic agents is strongly recommended in guidelines and has been shown to reduce bleeding and need for allogeneic blood administration. In the context of bleeding induced by anticoagulants and/or antiplatelet therapy, reversal strategies should be considered when available. Targeted goal-directed therapy using viscoelastic point-of-care monitoring is increasingly used to guide the administration of coagulation factors and allogenic blood products. In addition, damage control surgery, which includes tamponade of large wound areas, leaving surgical fields open, and other temporary maneuvers, should be considered when bleeding is refractory to hemostatic measures.
Copyright © 2023, the American Society of Anesthesiologists. All Rights Reserved.
Conflict of interest statement
Dr. Steiner reports the following: advisory committee for Octapharma (Paramus, New Jersey), DSMB for PumpKIN trial, hemostasis education for Medtronic (Dublin, Ireland), and U.S. Department of Defense contract “Chilled Platelet Study in Cardiac Surgery (CHIPS)” (Washington, D.C.). Dr. Ghadimi reports the following: research grant support from the International Anesthesia Research Society (San Francisco, California) and Octapharma. Dr. Levy reports the following: advisory committees for Instrumentation Labs (Bedford, Massachusetts), Merck (Rahway, New Jersey), and Octapharma. The other authors declare no competing interests.
Figures


References
-
- Sniecinski RM, Chandler WL: Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg. 2011; 113:1319–33 - PubMed
-
- Despotis GJ, Avidan MS, Hogue CW, Jr.: Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001; 72:S1821–31 - PubMed
-
- Levy JH, Dutton RP, Hemphill JC, 3rd, Shander A, Cooper D, Paidas MJ, Kessler CM, Holcomb JB, Lawson JH, Hemostasis Summit Participants: Multidisciplinary approach to the challenge of hemostasis. Anesth Analg. 2010; 110:354–64 - PubMed
-
- Adelborg K, Larsen JB, Hvas AM: Disseminated intravascular coagulation: Epidemiology, biomarkers, and management. Br J Haematol. 2021; 192:803–18 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical